Real-world Outcomes of Benralizumab in EGPA: A 24-Patient Series from a Severe Asthma Clinic in North India
Main Article Content
Abstract
ABSTRACT:
INTRODUCTION: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small- medium vessel vasculitis that has multisystem involvement. It is mostly seen in severe bronchial asthma patients. Eosinophils play a major pathological role in both the diseases. Targeted monoclonal antibodies have been emerging as a pivotal part of treatment. AIM: To study the clinical, radiological profile of patients of Eosinophilic granulomatosis with Polyangiitis (EGPA) and the response to treatment. Methods: A prospective study conducted in 24 confirmed EGPA patients at a tertiary care center in India. Clinical features, radiological patterns, laboratory markers, lung function parameters, and symptom scores were recorded at baseline and after 3 months of Benralizumab therapy. RESULTS: The mean age of cohort was 57.7 14.4 years, with females 54.2%. Asthma was present in 83.3% patients. 83.3% showed AEC >150 while P-ANCA was positive in 41.7% cases. Ground-glass opacities were the most common hrct chest finding (54.2%). Sinonasal disease occurred in 71%, skin involvement in 50%, and neuropathy in 20.8% cases. After 3 months of Benralizumab, significant improvements were observed across clinical and biomarker domains. Mean AEC decreased from 671 to 288 cells/L (p < 0.001), and mean total IgE declined from 1193 to 558 kU/L (p < 0.001). FEV?% predicted improved from 55% to 71% (p < 0.001). Number of patients with FeNO level <25 ppb increased from 41.7% to 83.3% (p <0.002). The mean ACT improved from 15 to 20 (p <0.001), indicating better symptomatic control. CONCLUSION: Patients with EGPA demonstrated characteristic clinical and radiological patterns, with early diagnosis enabled by 2022 EULAR criteria. Benralizumab produced significant improvements in eosinophilia, lung function, and symptom control within 3 months, supporting its role as an effective targeted therapy. Early recognition and biologic intervention may help prevent long-term organ damage and improve patient outcomes.
INTRODUCTION: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small- medium vessel vasculitis that has multisystem involvement. It is mostly seen in severe bronchial asthma patients. Eosinophils play a major pathological role in both the diseases. Targeted monoclonal antibodies have been emerging as a pivotal part of treatment. AIM: To study the clinical, radiological profile of patients of Eosinophilic granulomatosis with Polyangiitis (EGPA) and the response to treatment. Methods: A prospective study conducted in 24 confirmed EGPA patients at a tertiary care center in India. Clinical features, radiological patterns, laboratory markers, lung function parameters, and symptom scores were recorded at baseline and after 3 months of Benralizumab therapy. RESULTS: The mean age of cohort was 57.7 14.4 years, with females 54.2%. Asthma was present in 83.3% patients. 83.3% showed AEC >150 while P-ANCA was positive in 41.7% cases. Ground-glass opacities were the most common hrct chest finding (54.2%). Sinonasal disease occurred in 71%, skin involvement in 50%, and neuropathy in 20.8% cases. After 3 months of Benralizumab, significant improvements were observed across clinical and biomarker domains. Mean AEC decreased from 671 to 288 cells/L (p < 0.001), and mean total IgE declined from 1193 to 558 kU/L (p < 0.001). FEV?% predicted improved from 55% to 71% (p < 0.001). Number of patients with FeNO level <25 ppb increased from 41.7% to 83.3% (p <0.002). The mean ACT improved from 15 to 20 (p <0.001), indicating better symptomatic control. CONCLUSION: Patients with EGPA demonstrated characteristic clinical and radiological patterns, with early diagnosis enabled by 2022 EULAR criteria. Benralizumab produced significant improvements in eosinophilia, lung function, and symptom control within 3 months, supporting its role as an effective targeted therapy. Early recognition and biologic intervention may help prevent long-term organ damage and improve patient outcomes.
Article Details
How to Cite
TALWAR, Deepak et al.
Real-world Outcomes of Benralizumab in EGPA: A 24-Patient Series from a Severe Asthma Clinic in North India.
Medical Research Archives, [S.l.], v. 13, n. 12, jan. 2026.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/7152>. Date accessed: 02 jan. 2026.
doi: https://doi.org/10.18103/mra.v13i12.7152.
Keywords
EGPA, benralizumab, severe asthma, treatment response with biologicals, north india, AEC, FEV1, FENO, ACT
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.